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ABSTRACT: Recent interest in sulfhydryl cross-linked nonviral gene delivery systems,
designed to trigger the intracellular release of DNA, has inspired studies to establish
their utility in vitro. To determine if this concept can be extrapolated to in vivo gene
delivery, sulfhydryl cross-linking peptides (dp 20), derivatizedwith either anN-glycan or
polyethylene glycol (PEG), were used to generate sulfhydryl cross-linked gene
formulations. The biodistribution, metabolism, cell-type targeting, and gene expression
of sulfhydryl cross-linked PEG-peptide/glycopeptide DNA co-condensates were exam-
ined following i.v. dosing in mice. Optimal targeting to hepatocytes was achieved by
condensing 125I-DNAwithanadd-mixture of 10mol%triantennaryglycopeptide, 5mol%
PEG-peptide, and 85 mol % backbone peptide. Four backbone peptides were substituted
into the formulation to examine the influence of peptide metabolism and disulfide bond
strength on the rate ofDNAmetabolismand the level of gene expression in vivo. The half-
life of DNA in liver was extended from 1 to 3 h using a backbone peptide composed of
D-amino acids, whereas substituting penicillamine for cysteine failed to further increase
the metabolic stability of DNA. Optimized gene delivery formulations transiently
expressed secreted alkaline phosphatase inmouse serum for 12 days. The results suggest
that disulfide bond reduction in liver hepatocytes proceeds rapidly, followed by peptide
metabolism, ultimately limiting the metabolic half-life of sulfhydryl cross-linked DNA
condensates in vivo.  2003 Wiley-Liss, Inc. and the American Pharmaceutical Association J
Pharm Sci 92:1174–1185, 2003
Keywords: gene delivery; gene therapy; bioconjugates; DNA
INTRODUCTION
An optimal synthetic gene carrier must direct
DNA to overcome a cascade of extracellular and
intracellular barriers from the site of intravenous
injection to the nucleus of target cells.1–4 Cell
type-specific targeting can be achieved by deriva-
tizing peptides with a targeting ligand and a
nonionic hydrophilic polymer, such as polyethy-
lene glycol (PEG). The PEG performs the critical
function of protecting DNA colloids from serum
protein binding and recognition by the reticulo-
endothelial system (RES)5 while the targeting
ligand binds to cell surface receptors, facilitating
endocytosis of the DNA condensate.
Bioconjugate carriers composed of peptides,
polylysines, polyethylenimine, or dendrimerswith
covalently attached targeting ligand or PEG have
been used to mediate gene delivery. Although
peptide carriers are smaller and more homoge-
nous, they are not sufficiently stable during cir-
culation, resulting in premature dissociation of
the DNA carrier complex, nonspecific targeting
of DNA to the liver and rapid metabolism of
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naked DNA.2,6–8 One approach to increasing
DNA condensate stability provided by Anwer and
colleagues was dipalmitoylation to form a short
lipopeptide that, upon intravenous administra-
tion, mediated DNA uptake in the liver and
reporter gene expression.3
Several cross-linking strategies have also been
developed to stabilize peptide DNA condensates.
Homobifunctional agents, such as dimethyl-3,30-
dithiobispropionimidate, were used to cross-link
primaryamines on the surface of peptideDNAcon-
densates and thereby control their stability.9–11
Glutaraldehyde was also used to cross-link glyco-
peptide/PEG-peptide DNA condensates by form-
ing Schiffs bases between neighboring amines on
the surface of DNA condensates.2
Recently, sulfhydryl cross-linking peptides and
lipids were designed to undergo a template poly-
merizationwhen bound ionically to DNA resulting
in reversibly stabilized DNA condensates.12–16
In principle, the reducing environment of the
endosome and cytosol can trigger the release of
DNA intracellularly, which may account for the
improved gene transfer efficiency observed for
these reagents in vitro.14–16 Despite their demon-
strated activity in vitro, none of the sulfhydryl
cross-linked gene formulations under investiga-
tion have been evaluated for their ability to
mediate gene expression in vivo. In the present
study, we examine for the first time the in vivo
properties of sulfhydryl cross-linked peptide DNA
formulations by measuring their biodistribution,
metabolic stability, and transient gene expression.
The results indicate that despite their significant
reductive stability measured in vitro, the intracel-
lular reducing environment of the liver releases
DNA prematurely resulting in rapid meta-




Sodium 125I was purchased from Dupont NEN
(Boston, MA). Chloramine T, sodium metabisul-
fite, heparin, sodium dodecylsulfate (SDS),
Sephadex G-25, D-mannitol, bovine serum albu-
min, Hepes, collagenase from Clostridium histo-
lyticum type IV (lot number: 47H6865), carbonyl
iron were purchased from Sigma (St. Louis,
MO). Agarose was purchased from Gibco-BRL
(Gaithersburg, MD). Methoxy-PEG-vinylsulfone
5000 Da was purchased from Fluka (Ronkon-
koma, NY). SYBR-Gold was purchased from
Molecular Probes, Inc. (Eugene, OR). Ketamine
hydrochloride was purchased from Fort Dodge
Laboratories (Fort Dodge, IA). Tris(2-carbox-
yethyl)-phosphine hydrochloride (TCEP) was pur-
chased from Pierce (Rockford, IL). Xylazine
hydrochloride was purchased from Miles Inc.
(Shawnee Mission, KS). Silastic catheters
(0.305 mm i.d. 0.635 mm o.d.) were purchased
from Baxter (Obetz, OH). ICR mice (30–35 g)
were purchased from Harlan (Indianapolis, IN)
and housed in cages located in a limited access
area maintaining a 12-h light–dark cycle and con-
trolled temperature (26–288C). Ultrapure 100 and
tip100, DNA purification columns were purchased
from Qiagen (Santa Clarita, CA).
N-terminal Fmoc protected amino acids, 9-
hydroxybenzotriazole (HOBt), diisopropylcarbo-
diimide (DIC), and diisopropylethylamine were
obtained from Advanced ChemTech (Lexington,
KY) and Bachem (King of Prussia, PA). Substi-
tuted Wang resin for peptide synthesis was
obtained from Bachem (King of Prussia, PA).
N,N-Dimethyformamide, trifluoracetic acid (TFA),
acetic acid, acetonitrile, piperidine, and acetic
anhydride were purchased from Fisher Scientific
(Pittsburgh,PA). Peptide synthesiswasperformed
on a computer interfaced Model 90 Advanced
ChemTech solid phase peptide synthesizer (Lex-
ington, KY). Peptide purification was performed
using ananalytical or a semipreparative (5mm)C18
RP-HPLC column from Vydac (Hesperia, CA).
Preparative HPLC was performed using a compu-
ter-interfaced HPLC and fraction collector from
ISCO (Lincoln, NE). Electrospray mass spectro-
metry (ES-MS) was performed using a Thermo-
Finnigan LCQ mass spectrometer (San Jose, CA)
interfaced with an analytical HPLC from Hitachi
(San Jose, CA).
Radiolabeling Plasmid DNA
Endotoxin free plasmid DNA (5.1 kb), encoding a
secreted form of human placental alkaline phos-
phatase (pSEAP) with the SV40 early promoter
inserted upstream and the SV40 enhancer in-
serted downstream (Clontech, Palo Alto, CA), was
purified from Escherichia coli using a Qiagen
ultrapure column according to the manufacturers
instructions. Plasmid DNA was radiolabeled with
125I as described previously resulting in super-
coiled and circular DNA with specific activity of
250 nCi/mg.17
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Glycopeptide and PEG-Peptide Synthesis
and Characterization
Sulfhydryl cross-linking PEG-peptides and glyco-
peptides were synthesized and characterized as
reported previously.18 Glycopeptide 1 is composed
of a triantennary N-glycan attached through a
thiol ether linkage to the side chain of the N-
terminal Cys of Cys-Trp-Cys-(Lys)15-Cys-Lys
(Figure 1). PEG-peptide 2 is composed of a single
PEG5000 chain attached through a vinylic sulfone
linkage to the N-terminal Cys of Cys-Trp-(Cys-
Lys3)4-Cys-Lys (Figure 1). Four backbone pep-
tides (Figure 1, 3–6) were used to alter the stabi-
lity of sulfhydryl cross-linked DNA condensates.
Peptides 3 and 4 were L- or D-Cys-Trp-(Lys)5-Cys-
(Lys)5-Cys-(Lys)5-Cys, respectively, while pep-
tides 5 and 6 possessed L- or D-Pen-Lys-Trp-
(Lys)7-Pen-(Lys)8-Pen, where Pen is b,b-dimethyl
Cys. L-Cys peptide 3 and D-Cys peptide 4 were
synthesized as described previously.12 L-Pen pep-
tide 5 and D-Pen peptide 6were synthesized using
standard Fmoc procedures with 9-hydroxybenzo-
triazole (HOBt) and diisopropylcarbodiimide
(DIC) double couplings followed by N-capping
with acetic anhydride after each coupling to
avoid deletion sequences. Trityl (Trt) was used
to protect the side-chain thiol of Pen, whereas Lys
and Trp were protected with tertbutoxycarbonyl
(Boc). Following synthesis, peptides were cleaved
from the resin with simultaneous side-chain
deprotection with TFA/EDT/water (95:2.5:2.5 v/
v/v) for 2 h at room temperature. A low coupling
yield when attaching Pen to Trp necessitated
changing the sequence of the final three residues
on L-Pen peptide 5 and D-Pen peptide 6 from Pen-
Trp-Lys into Pen-Lys-Trp. Likewise, to improve
synthetic yields, the number of Pen residues in
5 and 6 were decreased from four to three. The
chemical identity of Pen peptides 5 and 6 were
verified by the LC-MS and LC-MS/MS.
Peptides were purified to homogeneity on RP-
HPLC by injecting 1 mmol onto a Vydac C18
semipreparative column (2 25 cm) eluted at
10 mL/min with 0.1% TFA and a gradient of
acetonitrile (5 to 25% over 30 min) while monitor-
ing tryptophan absorbance at 280 nm. The major
peak eluting at 24 min was collected and pooled
from multiple runs, lyophilized, and stored dry at
208C. Purified peptides were reconstituted in
0.1% TFA (degassed with nitrogen) and quantified
by tryptophan absorbance (e280¼ 5600 M1 cm1)
to determine the isolated yield was typically
20%.
Purified peptides were characterized by LC-MS
and LC-MS/MS by injecting 10 nmol onto a Vydac
C18 analytical column (0.47 25 cm) eluted at
1 mL/min with 0.1 v/v % acetic acid containing
0.02 v/v % TFA and an acetonitrile gradient of 1 to
25% over 30 min. The RP-HPLC eluent was
directly infused into the electrospray ionization
source of a ThermoFinnigan LCQ mass spectro-
meter and mass spectral data was obtained in the
positive mode.19,20
Formulation of Cross-linked Glycopeptide
and PEG-Peptide DNA Co-condensates
DNA co-condensates were prepared by add-mixing
a backbone peptide (85 mol %) with glycopeptide 1
(10 mol %) and PEG-peptide 2 (5 mol %) in HBM
(5 mM Hepes, 0.27 M mannitol, pH 7.4). pSEAP
(37.5 mg in 375 mL) was combined with either 7.5
or 15 nmol of peptide add-mixture in 375 mL of
HBM while vortexing. DNA co-condensates, pre-
pared at either 0.2 or 0.4 nmol of peptide per mg of
DNA corresponding to a charge ratio (NH4
þ/PO4
)
of 1:1 or 2:1, formed instantly and cross-linked
over 2 h but were allowed to equilibrate overnight
at 48C prior to analyzing particle size by quasi-
elastic light scattering (QELS) and zeta poten-
tial on a Zeta-Plus (Brookhaven Instruments,
Holtsville, NY).
Kinetics of Peptide Cross-linking
The kinetics of cross-linking within peptide DNA
condensates were studied indirectly by monitor-
ing the displacement of the SYBR-Gold interca-
lator dye from DNA condensates as a function of
time.12 Peptide DNA condensates were formed in
5 mM Hepes containing diluted (1:10,000) SYBR-
Gold by combining 0.5 mL (20 mg) of DNA with
0.5 mL (8 nmol) of peptide. Immediately after
mixing peptide and DNA, the fluorescence inten-
sity (Ex 495 nm, Em 537 nm) was continuously
monitored for 2 h.
Stability of Cross-linked DNA Condensates
The stability of cross-linked DNA co-condensates
was evaluated by adjusting 100 mL aliquots (5 mg
DNA) to 0, 0.4, 0.8, 1.0, 1.5, 2.0, and 2.5 M sodium
chloride (normalized to 300 mL with water)
followed by sonication for 30 s with a 100 W
Microson XL-2000 ultrasonic probe homogenizer
(Kontes, Vineland, NJ) with a vibrational ampli-
tude of 5 to fragment uncondensed DNA. Peptide
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Figure 1. Structure of glycopeptide 1, PEG-peptide 2, and peptides 3–6. The chemical
structure of eachbioconjuate carrier used is illustrated. L-Cyspeptide3and L-Penpeptide
5 are composed of all L-amino acids, whereas D-Cys peptide 4 and D-Pen peptide 6 are
composed of all D-amino acids.
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DNA co-condensates (0.5 mg per well) were digest-
ed with 30 mg of trypsin in 3 mL of Tris buffer
(50 mM Tris HCl, 7.5 mM CaCl2, pH 7.5) for 12 h
at 378C in 1 M sodium chloride, and then com-
bined with 3 mL of loading dye prior to electro-
phoresis on a 1% agarose gel and visualized by
ethidium bromide staining.
The reductive stability of cross-linked DNA
co-condensates was studied by gel retardation as
a function of increasing concentration of a redu-
cing agent. Peptide DNA co-condensates prepared
at 0.2 nmol of peptide per 0.5 mg of DNA per well
were reacted for 1.5 h at a final TCEP concentra-
tion of 0, 1, 3, 5, 10, 15, or 20mMina total volumeof
30 mL. Each sample was brought to 1 M sodium
chloride and then combined with 3 mL of loading
dye prior to electrophoresis on a 1% agarose gel
with 0.05% SDS and TAE buffer (40 mM Tris
acetate, 2 mM EDTA).
Biodistribution of 125I-DNA Co-condensates
Mice were anesthetized and a single catheter was
placed in the left jugular vein. 125I-DNA (2.5 mg in
50 mL of HBM, 0.6 mCi) or 125I-DNA condensates
were dosed i.v. followed by vein ligation. After 5,
15, 30, 60, 120, 240, 360, and 480 min, mice were
sacrificed by cervical dislocation and the major
organs (liver, lung, spleen, stomach, kidney,
heart, large intestine, and small intestine) were
harvested, rinsed with saline, and weighed. The
radioactivity in each organ was determined by
direct g-counting and expressed as the targeting
efficiency, defined as the percent of the dose in the
target organ.
Isolation of Hepatocytes and Kupffer Cells
Mice were dosed i.v. tail vein with 20 mg of
carbonyl iron in 0.2 mL of saline. After 45 min,
mice were anesthetized and a single catheter was
inserted into the right jugular vein and used to
dose 125I-DNA co-condensates (2.5 mg DNA in
50 mL, 0.6 mCi in HBM). Following 30 min of
biodistribution, the portal vein was cannulated
and used to administer 0.2 mL heparin (100 U/
mL) followed immediately by the perfusion buf-
fers. The liver was first perfused at 5 mL/min for
2 min with oxygenated (95% oxygen, 5% carbon
dioxide) preperfusion buffer (calcium and magne-
sium free Hepes solution, pH 7.45, 378C), and
then at 3 mL/min for an additional 3 min. The
liver was digested by perfusion with oxygenated
Seglen’s Buffer (pH 7.45, 378C) containing 0.058%
(w/v) collagenase type IV at 3 mL/min for 16–
20 min. At the start of the perfusion the vena cava
and aorta were cut, and at the completion, the
liver was excised and placed in a Petri dish (48C)
and cut into small pieces. Cells were dislodged
and dispersed in ice-cold Hank’s solution con-
taining 10 mM Hepes, pH 7.45, 0.1% BSA and
then incubated at 378C for 20 min with shaking
(30 rev/min). The dispersed cells were passaged
through a 73-mm mesh filter then transferred to a
35-mL glass tube. The iron-filled Kupffer cells
were attracted to the wall of the tube with a
magnet while other cells were decanted off. The
procedure was repeated three times and the
Kupffer cells were combined and resuspended in
0.8 mL Hank’s Hepes Buffer. The remaining cell
suspension was centrifuged at 50 g for 1 min
and the supernatant was discarded. The pelleted
hepatocytes were washed twice with ice-cold
Hank’s–Hepes buffer followed by centrifuging
at 50 g for 1 min. The hepatocytes were re-
suspended in 2 mL Hank’s–Hepes buffer, and the
cell number and viability were determined by the
trypan blue exclusion method. The amount of
radioactivity associated with each cell fraction
was determined by g-counting.
In Vivo Gene Expression
Four mice were dosed in the tail vein by infusing
1 mL over 10 min of HBM containing either 50 mg
of plasmid DNA or 50 mg of a DNA formulation.
Blood (30 mL) was collected via the tail vein from
four mice at day 1, 3, 6, 9, 12, 15, 18, 21, 25, and 30
after dosing. The blood was allowed to clot at room
temperature, centrifuged at 13,000 g for 15 min,
and the serum that was collected was stored
frozen at 208C until assayed for SEAP.
The chemiluminescent SEAP assay (Clontech,
Palo Alto, CA) was used as instructed by the
manufacturer. Briefly, 5 mL of mouse serum was
added to 5 mL of the dilution buffer provided by the
kit. Standard curves were generated by diluting
human placental alkaline phosphatase with blank
mouse serum. Samples and standards were placed
in 1.5 mL microcentrifuge tubes and heated for
30 min at 658C to deactivate endogenous alkaline
phosphatase. After cooling on ice for 5 min, the
samples were brought to room temperature, and
10 mL of assay buffer was added followed by 10 mL
of substrate diluted with chemiluminescent en-
hancer. After a 45-min incubation, luminescence
wasmeasured on a luminometer (Turner Designs,
Sunnyvale, CA) by integrating for 5 s. Relative
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light units were converted into SEAP concentra-
tion (ng/mL of serum) using a standard curve.
RESULTS
Characterization of Sulfhydryl Cross-linked
DNA Co-condensate Formulations
To determine if sulfhydryl cross-linking peptides
could achieve selective targeting and expression
in vivo, gene formulations were developed that
target the asialoglycoprotein receptor on hepato-
cytes (Scheme 1). Previous experiments demon-
strated that as little as 2 mol % of a triantennary
glycopeptide could selectively target glutaralde-
hyde cross-linked DNA condensates to hepato-
cytes while PEG-peptides were determined to be
essential to block nonspecific recognition by RES
cells.2
In addition to a sulfhydryl cross-linking glyco-
peptide and PEG-peptide (Figure 1), a third
peptide component was substituted into the
formulation to modulate the metabolic stability
of the DNA. Four different backbone peptides
possessing L- or D-amino acids containing either
cysteine (Cys) (Figure 1, 3 and 4) or penicillamine
(Pen) (Figure 1, 5 and 6) were substituted into the
formulation. Because Pen disulfide bonds are
nearly 60-fold more reductively stable than those
formed with Cys,21 comparison of DNA formula-
tions prepared with 85 mol % of L-Cys peptide 3 or
L-Pen peptide 5 with D-Cys peptide 4 or D-Pen
peptide 6 were used to determine if disulfide bond
strength or peptide dissociation and/or metabo-
lismwas the rate limiting step in themetabolismof
DNA condensates.
Because the size and charge of DNA conden-
sates strongly influence the in vivo performance of
a gene delivery system, electronegative and elec-
tropositive DNA formulations were prepared at
either a 1:1 or 2:1 charge ratio. QELS analysis
established that regardless of charge, sulfhydryl
cross-linked peptide DNA co-condensates formed
small particles with a mean diameter of less than
100nm(Table 1).Electronegative condensateshad
a zeta potential of approximately 14–16 mV,
whereas electropositive condensates possessed a
zeta potential of þ14–21 mV (Table 1).
When bound to DNA, cross-linking peptides are
less flexible, rendering intermolecular peptide
Scheme 1. Preparation of sulfhydryl cross-linked peptide DNA co-condensates.
Peptide DNA co-condensates were formed by reaction of plasmid DNA with an add-
mixture of glycopeptide1, PEG-peptide2, and one of either peptide3–6. The add-mixture
ratio is systemically varied to optimize hepatocyte targeting and gene expression.
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cross-linking as the preferred route of oxidation.12
A continuous fluorescence assay using SYBR-Gold
as a DNA intercalator dye was used to determine
the time course of interpeptide disulfide bond
formation for peptides bound to DNA (Figure 2).
At a charge ratio of 2:1, alkylated CWK18 formed
DNA condensates instantly and produced a nearly
constant SYBR-Gold fluorescence intensity over
2 h.12 In contrast, the fluorescence intensity de-
creased over 30 min and reached an asymptote in
2 h when using formulation E or G (Table 1)
composed of L-Cys peptide 3 and L-Pen peptide 5,
respectively (Figure 2). The kinetic decrease in
SYBR-Gold fluorescence was interpreted as the
time course of disulfide formation for peptides
bound to DNA as has been demonstrated for other
sulfhydryl cross-linking peptides, which upon
polymerization more efficiently displace fluoro-
phore due to higher binding affinity for DNA.12
The stability of fully oxidized sulfhydryl cross-
linked DNA condensates were evaluated as a
function of increasing sodium chloride concentra-
tion to establish the nature of the disulfide cross-
links with DNA condensates.12,22,23 Previous
studies established that 20 amino acid peptides
possessing two terminal Cys residues linearly
polymerized and formed DNA condensates that
were stable up to 1 M sodium chloride, whereas
peptides with three Cys residues formed DNA
condensates that were stable in 2.5 M sodium
chloride.12 When peptide and DNA dissociate at a
critical salt concentration, sonication leads to the
fragmentation of OC and SC bands with the
formation of a heterogeneous smear of smaller
oligonucleotides.12,22,23 The results presented in
Figure 3A and B demonstrate that formulation C
Figure 2. Kinetics of cross-linkingDNAcondensates.
The fluorescence intensity of intercalated SYBR-Gold
was continuouslymonitored over timeduring the forma-
tion of peptide DNA condensates prepared with alky-
lated CWK18 (&), and formulation E composed of L-Cys
peptide 3 (^) and formulation G composed of L-Pen
peptide 5 (*). The results indicate a decrease in fluore-
scence over time for formulations composed of cross-
linking peptides but not for alkylated CWK18.









A 69 10 13.0 2.6 46 6 54 6
B 71 7 16.1 1.8 65 4 35 4
C 64 12 15.0 5.9 76 1 24 1
D 87 13 14.4 1.5 45 3 55 3
E 80 9 18.1 2.9 89 2 11 2
F 82 9 19.6 3.0 84 4 16 4
G 77 8 21.5 3.5 84 2 16 2
H 95 10 19.8 4.3 82 2 18 2
aEach formulationwasprepared at a concentration of 50mg/mLDNAandat a stoichiometry of 0.2
or 0.4 nmol of total peptides per mg of DNA corresponding to the charge ratio of 1:1 or 2:1.
A¼glycopeptide 1/PEG-peptide 2/L-Cys peptide 3 (0/5/95 at a charge ratio of 1:1).
B¼glycopeptide 1/PEG-peptide 2/L-Cys peptide 3 (5/5/90 at a charge ratio of 1:1).
C¼glycopeptide 1/PEG-peptide 2/L-Cys peptide 3 (10/5/85 at a charge ratio of 1:1).
D¼glycopeptide 1/PEG-peptide 2/D-Cys peptide 4 (0/15/85 at a charge ratio of 2:1).
E¼glycopeptide 1/PEG-peptide 2/L-Cys peptide 3 (10/5/85 at a charge ratio of 2:1).
F¼ glycopeptide 1/PEG-peptide 2/D-Cys peptide 4 (10/5/85 at a charge ratio of 2:1).
G ¼ glycopeptide 1/PEG-peptide 2/L-Pen peptide 5 (10/5/85 at a charge ratio of 2:1).
H¼glycopeptide 1/PEG-peptide 2/D-Pen peptide 6 (10/5/85 at a charge ratio of 2:1).
bParticle size is reported as the mean diameter and standard deviation of five measurements.
cZeta potential is reported as the mean and standard deviation of 10 measurements.
dCalculated as the percent of count per minute (cpm) in recovered hepatocytes (106) and Kupffer
cells (105) over time.
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and E, representing electronegative and electro-
positive formulations composed of L-Cys peptide 3,
protected DNA from fragmentation in 2.5 M
sodium chloride. Apparently, upon binding to
DNA, both linear polymerizationand cross-linking
occurred within peptide DNA condensates. The
increase in salt concentration across the gel
systematically retarded the migration of OC and
SC DNA bands (assigned by comparison to
standards), but no evidence of DNA fragmentation
is observed (Figure 3).
The reductive stabilityof sulfhydryl cross-linked
DNAcondensateswere compared by visual inspec-
tion of theDNA band intensity following reduction
with increasing TCEP concentration. At a TCEP
concentration of 1 mM or lower, formulation E,
composed of L-Cys peptide 3, prohibited the release
of the DNA (Figure 4A, lanes 2 and 3), whereas at
3–20 mM, reduction of disulfide bonds caused the
release of DNA from the condensates allowing
recovery of bands on the gel (Figure 4A, lanes 4–8).
By comparison, formulation G, composed of L-Pen
peptide 5, completely resisted reduction by TCEP
up to 20mM (Figure 4B, lanes 2–8) indicating that
the Pen peptide has significantly higher reductive
stability than the Cys peptide. Equivalent results
were obtained for formulations F and H, posses-
sing D-Cys or D-Pen peptides 4 and 6, respectively
(results not shown).
In Vivo Evaluation of Sulfhydryl Cross-linked
DNA Co-condensates
To achieve maximal hepatocyte targeting selec-
tivity, the stoichiometry of glycopeptide 1 was
varied while monitoring targeting efficiency to
hepatocytes. Previous studies have established
the biodistribution equivalency of formulations
possessing between 2.5 and 50 mg of DNA.2
Formulation A (Table 1), which lacked a glyco-
peptide, distributed with 46% associated with
hepatocytes and 54% with Kupffer cells, whereas
formulation B, containing 5 mol % glycopeptide,
improved the targeting specificity to 65% asso-
ciated with hepatocytes. Increasing the glycopep-
tide to 10 mol % in formulation C increased
hepatocyte targeting to 76%, whereas increasing
the amount of PEG-peptide 2 did not improve the
targeting selectivity. Comparison of formulation
C and E established that electropositive formula-
tions target hepatocytes with greater selectivity
(Table 1). Biodistribution studies performed on
electronegative DNA formulations A–C estab-
lished the liver as the major target site at 15
min, resulting in a targeting efficiency of 55%
with all other organs possessing <10% of the 125I-
DNA dose (Figure 5A). Analysis of the elimination
rate of 125I-DNA from the liver established a t1/2
for DNA of approximately 1 h for formulation
Figure 3. Shear stress stability of cross-linked peptide DNA co-condensates. The
stability of cross-linkedDNAcondensatesweremeasuredbygel electrophoresis following
a 30-s sonication in the prescence of increasing sodium chloride concentration. Lanes 1
through 7 represent 0, 0.4, 0.8, 1.0, 1.5, 2.0, and 2.5 M sodium chloride in the sonication
solutions. Peptide DNA condensates were prepared using formulation C (A) or
formulation E (B), both composed of L-Cys peptide 3 (Table 1). The results demonstrate
the equivalent stability of electronegative and electropositive sulhydryl cross-linked
DNA condensates.
IN VIVO GENE TRANSFER 1181
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 92, NO. 6, JUNE 2003
A–C (Figure 6A–C), which is slightly longer than
that of plasmid DNA that is rapidly eliminated
from the liver with a t1/2 of 0.6 h.
2 This result
suggests that cross-linked electronegative DNA
condensates only weakly protect DNA from meta-
bolism in the liver. The finding that increasing the
mol % of glycopeptide in formulation B and C
improved selective targeting to hepatocytes sup-
ports the hypothesis that cross-linked conden-
sates remain intact in circulation. We conclude
that electronegative sulfhydryl cross-linked pep-
tide DNA condensates undergo rapid metabolism
in the liver perhaps due to endonuclease attack of
exposed DNA.
Electropositive DNA condensates should pro-
vide greater protection from metabolism due to
complete ion pairing of peptide with DNA. Bio-
distribution analysis of electropositive DNA co-
condensates established the liver as the major
target site at 15min for all formulations, resulting
in a targeting efficiency of approximately 50%
(Figure 5BandC). A similar biodistribution profile
was observed at 30 and 60 min for each formula-
tion with proportional decreases in the liver
targeting over time, without significant increases
in the distribution to other tissues. The biodistri-
bution time was extended to 8 h to determine the
half-life of 125I-DNA in the liver. At 2 h the 125I-
DNA remaining in the liver was threefold higher
for formulations D–H relative to that obtained
with uncross-linked DNA condensates.2 As dis-
cussed above, otherwise identical peptide DNA
condensates prepared at a charge ratio of 2:1
exhibited a longer liver half-life than those pre-
pared at a charge ratio of 1:1 (Figure 6C versus E).
Substitution of peptides containing Pen for Cys
(Figure 6E versus G or Figure 6F versus H) esta-
blished that disulfide bond strength did not in-
fluence themetabolic half-life of DNA condensates
in the liver. Alternatively, comparison of formula-
tion E and F (Figure 6E versus F) or G and H
(Figure 6G andH) established that replacement of
L-amino acids with D-amino acids increased the
Figure 4. Reductive stability of sulfhydryl cross-
linked peptide DNA co-condensates. The stability of
cross-linked DNA co-condensates prepared with formu-
lation E (A) andG (B) are compared by recovery of bands
on gel electrophoresis. DNA formulations were treated
with increasing concentrations of TCEP (lanes 2–8, 0, 1,
3, 5, 10, 15, and 20 mM) and compared to plasmid DNA
treated with 20 mM TCEP (lane 1). The results indicate
that formulation E, composed of L-Cys peptide 3,
released DNA whereas formulation G, composed of L-
Pen peptide 5, does not.
Figure 5. Biodistribution of 125I-DNA condensates in
mice. The targeting efficiency (percent of dose in the
organ) was determined for 125I-DNA formulations in
the tissues at 5, 15, 30, and 60 min. (A–C) Displays the
biodistribution profile of DNA formulations C, E, and F,
respectively. The data represent themean and standard
deviation of triplicate mice.
1182 KWOK ET AL.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 92, NO. 6, JUNE 2003
liver half-life of DNA nearly twofold with 23%
remaining in the liver at 4 h. These results suggest
that peptide reduction of sulfhydryl cross-linked
DNA co-condensate is most likely not the rate
limiting step ofDNAcondensatemetabolism in the
liver. A rapid reduction of the peptides on DNA
followed by a rate limiting dissociation and pro-
teolytic cleavage is the most likely route of meta-
bolism. This mechanism is supported by the
finding that regardless of the reductive stability,
sulfhydryl cross-linking peptides composed of D
amino acids retard the rate of DNA metabolism
in vivo.
Sulfhydryl cross-linked peptide DNA co-
condensates were able to mediate SEAP expres-
sion in vivo. Analysis of the transient SEAP
expression profile demonstrated a detectable
gene expression at day 1, which peaked at day 7
at 3–5 ng/mL and returned to baseline levels by
day 12 (Figure 7). Formulations E–H produced
nearly equivalent transient gene expression pro-
files. Control formulation D, containing no target-
ing ligand, failed to produce gene expression, an
identical result to that obtained when dosing
naked plasmid DNA (Figure 7). Notably, the
relatively short half-life of SEAP in blood (17 h)
suggests that the gene product detected in serum
is the result of ongoing gene expression rather
than persistent circulation of active protein in the
serum.24
DISCUSSION
One function of polylysine and other polymers
used as carriers for gene delivery is to protect
DNA from premature metabolism.6,23 The degree
of metabolic protection afforded to DNA by
polylysine is proportional to its molecular weight
because longer polylysines bind to DNA with
higher affinity and create more stable peptide
DNA condensates.6 An alternative strategy is to
stabilize DNA formulations by cross-linking.2
Sulfhydryl cross-linking peptides that form rever-
sible interpeptide disulfide linkages12,13 could
offer an advantage over irreversible cross-linkers
that limit the accessibility of the DNA for trans-
cription and, hence, reduce gene expression.22
Once internalized, the reducing environment
could trigger disulfide bond reduction and intra-
cellular release of DNA for gene expression.
Stable electronegative and electropositive pep-
tide DNA condensates could be prepared because
Figure 6. Liver biodistribution profile for 125I-DNA
formulations in mice. The time course of liver targeting
and elimination of i.v. dosed 125I-DNA formulations in
mice are illustrated. (A–H) Illustrate the liver targeting
efficiency (% of dose in liver) and the metabolic half-life
for DNA formulations A–H (Table 1). Each result
represents the mean and standard deviation of three
independent analyses.
Figure 7. In vivo gene expression of sulfhydryl cross-
linked DNA co-condensates. The 1-month gene expres-
sion profile of SEAP in mice is compared following a
single 50-mg tail vein dose of DNA formulations D–H
(Table 1) and naked plasmid DNA. Each formulation
produced significantly higher levels of SEAP (p< 0.05)
at day 7 relative to a control formulation (D). Each data
point represents the mean and standard error for four
mice.
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sulfhydryl cross-linking is independent of peptide/
DNA stoichiometry. At either charge ratio, elec-
trophoretic analysis established that sulfhydryl
cross-linked DNA co-condensates were stable
against sonicative shear stress up to 2.5 M sodium
chloride (Figure 3). The reductive stability of
sulfhydryl cross-linked DNA condensates were
also significantly greater when substituting Pen
peptide for Cys peptide (Figure 4). To endow the
delivery system with targeting specificity and
simultaneously shield the surface charge of DNA
condensates, peptides were conjugated to either a
natural triantennary N-glycan ligand or PEG
resulting in glycopeptide 1 and PEG-peptide 2.
Electronegative formulations A–C formed
small particles that avoided lung targeting
(Figure 5A) more efficiently than electropositive
particles, suggesting that a negative charge is
advantageous in minimizing opsonization of DNA
condensates in the blood to ensure good tissue
dissemination after i.v dosing. An optimal formu-
lation resulted in a higher specific uptake by
hepatocytes (76%) than Kupffer cells (24%). How-
ever, the short half-life of DNA in the liver
suggested that electronegative DNA condensates
are more susceptible to serum nucleases.
Electropositive DNA formulations were more
successful at mediating specific targeting to hepa-
tocytes via the asialoglycoprotein receptor and
achieving a longer liver half-life. Although for-
mulations D–H were positively charged they
avoided targeting to the lung as the primary site
due to the use of aPEG-peptide, whereaswithout a
PEG-peptide, electropositive DNA condensates
have been shown to bind to serum proteins and
are primarily trapped in the capillary beds of
the lung.2
Formulations composedof D-aminoacids formed
condensates that were more stable in the liver re-
lative to identical formulations possessing L-amino
acids. This result is analogous to that reported
when analyzing DNA formulations prepared with
L- or D-polylysine.25 What was unexpected was
the nearly identical short liver half-life of DNA
condensates prepared using Cys versus Pen con-
taining peptides. Although L-Pen peptide 5 con-
tained only three Pen residues, it formed DNA
condensates that were significantly more reduc-
tively stable than peptide L-Cys peptide 3 DNA
condensates possessing four Cys residues per
peptide (Figure 4). This indicates that regardless
of the strength of the disulfide bonds, reduction of
the peptide proceeds faster than proteolysis to
release DNA in lysosomes. When proteolysis is
blocked by the use of D peptides, reduction of the
disulfide bonds followed by dissociation of mono-
meric peptides is the proposed route of DNA
release. This process is slower, accounting for the
longer liver half-life of DNA, but was also not
influenced by the nature of the disulfide bonds.
These findings suggest that the concentration
of endogenous thiols, such as glutathione, are
sufficient to reduce even highly stabilized DNA
condensates resulting in a relatively short liver
half-life of 2.5 h.
The SEAP reporter gene was chosen to permit
sensitive detection of serially sampled blood time
points from individualmice.26 In vivo expression of
SEAPpeaked at day 7 and lasted for 12 dayswith a
level comparable to a previous study.27 Compar-
ison of the sulfhydryl cross-linked DNA conden-
sates established an identical transient gene
expression profile regardless of backbone peptide.
In the absence of glycopeptide or carrier peptides,
mice failed to produce measurable levels of SEAP.
These results are consistent with previous studies
that also determined a dependency on ligand to
achieve alpha-1-antitrypsin gene expression, and
found that aDNA liverhalf-life of less than3honly
produced low levels of gene product.2,28
In conclusion, the results presented demon-
strate that it is possible to use a combination of
peptide conjugates to achieve cell-type specific
gene delivery and transient gene expression in
mouse liver by means of sulfhydryl cross-linking.
These carriers offer the advantage of controlled
synthesis and defined purity to allow strategic
optimization to increaseexpression levels.Further
studies will be needed to optimize these carriers
to increase the metabolic half-life and the level
of transient gene expression. This will likely in-
volve the application of cross-linking strategies
with transmembrane activity to assist endosomal
escape.
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